Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Net Income (2020 - 2025)

Barinthus Biotherapeutics' Net Income history spans 6 years, with the latest figure at -$11.1 million for Q4 2025.

  • For Q4 2025, Net Income rose 46.08% year-over-year to -$11.1 million; the TTM value through Dec 2025 reached -$66.5 million, down 8.62%, while the annual FY2025 figure was -$66.5 million, 8.62% down from the prior year.
  • Net Income reached -$11.1 million in Q4 2025 per BRNS's latest filing, up from -$14.6 million in the prior quarter.
  • In the past five years, Net Income ranged from a high of $15.7 million in Q2 2022 to a low of -$23.8 million in Q2 2023.
  • Average Net Income over 5 years is -$12.2 million, with a median of -$16.1 million recorded in 2021.
  • Peak YoY movement for Net Income: skyrocketed 248.69% in 2022, then tumbled 807.96% in 2023.
  • A 5-year view of Net Income shows it stood at -$16.7 million in 2021, then dropped by 26.59% to -$21.2 million in 2022, then rose by 18.3% to -$17.3 million in 2023, then dropped by 19.09% to -$20.6 million in 2024, then soared by 46.08% to -$11.1 million in 2025.
  • Per Business Quant, the three most recent readings for BRNS's Net Income are -$11.1 million (Q4 2025), -$14.6 million (Q3 2025), and -$21.1 million (Q2 2025).